Publications by authors named "Maria Fernandez-Saorin"
Front Pharmacol
January 2024
Article Synopsis
- Docetaxel is the standard treatment for advanced prostate cancer, but many patients develop resistance due to certain cell signaling pathways becoming overly active.
- This study investigates the combined inhibition of the PI3K/AKT and MEK/ERK pathways in prostate cancer cells that are resistant to docetaxel, showing that this combo treatment can reduce cell growth and promote cancer cell death.
- The results suggest that using selumetinib and AZD8186 together could be a new therapeutic approach for patients with a specific type of docetaxel-resistant prostate cancer, paving the way for future clinical trials.
